uniQure N.V. (NASDAQ:QURE – Get Free Report) Director Madhavan Balachandran sold 11,685 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total transaction of $526,526.10. Following the sale, the director directly owned 43,254 shares in the company, valued at approximately $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Madhavan Balachandran also recently made the following trade(s):
- On Monday, June 15th, Madhavan Balachandran sold 10,000 shares of uniQure stock. The shares were sold at an average price of $27.85, for a total value of $278,500.00.
- On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total value of $53,930.58.
uniQure Stock Performance
NASDAQ QURE opened at $48.85 on Thursday. The stock has a market capitalization of $3.08 billion, a price-to-earnings ratio of -14.04 and a beta of 0.98. uniQure N.V. has a twelve month low of $8.73 and a twelve month high of $71.50. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average of $26.59 and a 200 day moving average of $22.65.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC grew its holdings in shares of uniQure by 38.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after buying an additional 1,705,556 shares in the last quarter. Aberdeen Group plc lifted its stake in shares of uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares in the last quarter. State Street Corp lifted its stake in shares of uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after buying an additional 1,787,033 shares in the last quarter. JPMorgan Chase & Co. boosted its position in uniQure by 155.3% during the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its position in uniQure by 189.7% during the first quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock worth $34,926,000 after acquiring an additional 1,398,749 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on QURE shares. Chardan Capital boosted their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Stifel Nicolaus set a $28.00 target price on shares of uniQure in a research report on Tuesday, May 5th. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Cantor Fitzgerald upgraded shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target for the company in a research report on Wednesday, June 17th. Finally, Royal Bank Of Canada raised their price target on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Twelve investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $58.92.
Get Our Latest Stock Analysis on uniQure
uniQure News Roundup
Here are the key news stories impacting uniQure this week:
- Positive Sentiment: uniQure completed pricing on an upsized offering of 4,945,055 ordinary shares at $45.50 each, expected to raise about $225 million in gross proceeds. The added capital should strengthen the balance sheet and help fund its gene therapy pipeline. Article Title
- Neutral Sentiment: The company said the offering is expected to close around June 25, with underwriters also having a 30-day option to buy additional shares. This keeps financing flexibility high, but the near-term impact depends on completion and investor reception. Article Title
- Negative Sentiment: Investors appear worried about dilution because the company is issuing new shares rather than using debt. That pressure likely contributed to the stock’s weakness despite the capital raise. Article Title
- Negative Sentiment: Recent insider selling by the CEO and several directors may also weigh on sentiment, even though some trades were made under pre-arranged plans. Article Title
uniQure Company Profile
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Featured Stories
- Five stocks we like better than uniQure
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
